Article date: January 1991
By: A Herchuelz, D Gangji, F Derenne, JP Jeanniot, J Douchamps, in Volume 31, Issue 1, pages 73-76
1. Almitrine bismesylate displays wide inter‐subject variation in peak plasma concentrations and can induce peripheral polyneuropathy. 2. The phenotyped volunteer panel approach was used to examine whether almitrine oxidation displayed a genetic polymorphism of the debrisoquine/sparteine type. 3. There was no difference between poor and extensive metabolisers of debrisoquine with respect to the pharmacokinetics and metabolism of almitrine.
DOI: 10.1111/j.1365-2125.1991.tb03859.x
View this article